A new class of anti-diabetic compound has been identified by scientists at Scripps Research Institute, potentially paving the way for better medications for the condition likely to benefit those with the disease using home care.
The research, published in journal Nature, detailed a new category of anti-diabetic compound designed to target a unique molecular switch.
It is hoped that these findings will lead to new treatments for diabetes, which have fewer adverse side effects than those currently on the market.
Professor Patrick R Griffin, study leader, commented: "This unique mechanism of action appears to significantly limit side effects associated with marketed drugs."
Researcher Bruce Spiegelman added: "It appears that we may have an opportunity to develop entire new classes of drugs for diabetes and perhaps other metabolic disorders."
This follows research published in the Proceedings of the National Academy of Sciences which found that the mitochondria of cells is decreased in the skeletal muscle of people with diabetes.
The new target could be used to treat type 2 diabetes and prediabetes, researchers have said.
Find the nearest Barchester care home